免疫比浊法试剂市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用和地区细分，竞争情况，2020-2030 年

2024 年全球免疫比浊试剂市场价值为 54 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 6.10%。这种特殊类型的分析依赖浊度测定原理，可以测量溶液的浊度或混浊度。在免疫比浊法中，此方法用于定量测定患者血液样本中的特定蛋白质或物质。此过程首先将患者的血清或血浆样本引入含有针对目标蛋白质或分析物的特定抗体的试剂中。如果样本中存在目标蛋白质，它就会与抗体结合，形成免疫复合物。这些复合物会使穿过溶液的光发生散射，导致浊度增加。浊度的变化与目标分析物的浓度成正比。免疫比浊法试剂是该过程的关键组成部分，因为它们含有形成免疫复合物所必需的特定抗体。

这些试剂经过精心配製，确保高特异性和灵敏度，可准确量化目标蛋白质。此外，它们的设计旨在最大限度地减少样品中其他物质的干扰，确保结果精确可靠。免疫比浊法的主要优点之一是它广泛适用于一系列分析物，包括 C 反应蛋白 (CRP)、免疫球蛋白和补体蛋白等蛋白质。这使得它成为临床实验室中评估各种疾病状态和监测患者健康状况的多功能工具。此外，免疫比浊法测定相对较快，能够及时提供结果，这对于及时的临床决策至关重要。此外，免疫比浊法可实现自动化，从而可以对患者样本进行高通量分析。这提高了临床实验室的效率，使他们能够在更短的时间内处理大量测试。免疫比浊法的自动化也减少了人为错误的可能性，进一步确保了结果的准确性和可靠性。

主要市场驱动因素

慢性病和传染病发生率上升

主要市场挑战

自动化免疫化学产品采用率低

主要市场趋势

自动化和高通量诊断系统的采用日益增多

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：免疫比浊法试剂市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（普通免疫比浊试剂、乳胶增强免疫比浊试剂）
  • 依应用分类（糖化血红素、视黄醇结合蛋白、C 反应蛋白、抗链球菌溶血素「O」、类风湿因子、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美免疫比浊法试剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第七章：欧洲免疫比浊法试剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太免疫比浊法试剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲免疫比浊法试剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲免疫比浊法试剂市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球免疫比浊法试剂市场：SWOT 分析

第 14 章：竞争格局

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Immunoturbidimetry Reagents Market was valued at USD 5.40 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.10% till 2030. Immunoturbidimetry reagents play a pivotal role in clinical diagnostics, particularly in the field of immunology. This specialized type of assay relies on the principle of turbidimetry, which measures the degree of turbidity or cloudiness in a solution. In immunoturbidimetry, this method is employed to quantitatively determine specific proteins or substances in a patient's blood sample. The process begins by introducing a patient's serum or plasma sample to a reagent containing antibodies specific to the target protein or analyte. If the target protein is present in the sample, it will bind with the antibodies, forming immune complexes. These complexes scatter light passing through the solution, resulting in an increase in turbidity. This change in turbidity is directly proportional to the concentration of the target analyte. Immunoturbidimetry reagents are crucial components of this process, as they contain the specific antibodies necessary for the formation of immune complexes.

These reagents are meticulously formulated to ensure high specificity and sensitivity, allowing for accurate quantification of the target protein. Moreover, they are designed to minimize interference from other substances in the sample, ensuring precise and reliable results. One of the key advantages of immunoturbidimetry is its wide applicability across a range of analytes, including proteins like C-reactive protein (CRP), immunoglobulins, and complement proteins. This makes it a versatile tool in clinical laboratories for assessing various disease states and monitoring patient health. Additionally, immunoturbidimetry assays are relatively rapid, providing timely results that are crucial for timely clinical decision-making. Furthermore, immunoturbidimetry is amenable to automation, allowing for high-throughput analysis of patient samples. This enhances the efficiency of clinical laboratories, enabling them to process a large volume of tests in a shorter timeframe. The automation of immunoturbidimetry also reduces the potential for human error, further ensuring the accuracy and reliability of results.

Key Market Drivers

Rising Prevalence of Chronic and Infectious Diseases

The increasing prevalence of chronic and infectious diseases is a significant driver propelling the expansion of the Global Immunoturbidimetry Reagents Market. As healthcare systems worldwide focus on early disease detection, monitoring, and effective management, the demand for high-precision diagnostic solutions such as immunoturbidimetry-based assays continue to rise. Chronic diseases, also known as non-communicable diseases (NCDs), have become the leading cause of mortality and morbidity worldwide. Conditions such as cardiovascular diseases (CVDs), diabetes, kidney diseases, autoimmune disorders, and cancer require continuous monitoring and early detection, creating a strong demand for accurate, reliable, and cost-effective diagnostic reagents like immunoturbidimetry reagents. According to a 2023 report by the World Heart Federation (WHF), global deaths from cardiovascular disease (CVD) surged from 12.1 million in 1990 to 20.5 million in 2021, reflecting a sharp increase in disease prevalence and associated risk factors. CVD remained the leading cause of death worldwide in 2021, with 80% of fatalities concentrated in low- and middle-income countries (LMICs). This trend underscores the urgent need for targeted healthcare investments, improved diagnostic capabilities, and scalable treatment solutions in these high-burden regions.

Biomarkers such as high-sensitivity C-reactive protein (hs-CRP), apolipoproteins (Apo A1 & Apo B), and fibrinogen are crucial for assessing cardiovascular risk and disease progression. Immunoturbidimetry reagents enable fast and cost-effective quantification of these biomarkers in routine clinical settings, increasing their adoption in diagnostic laboratories. By 2045, projections from the International Diabetes Federation (IDF) indicate that one in eight adults-approximately 783 million people-will be living with diabetes, marking a 46% increase from current levels. Notably, over 90% of cases will be type 2 diabetes, driven by a complex interplay of socioeconomic disparities, shifting demographics, environmental influences, and genetic predisposition. Regular monitoring of glycated hemoglobin (HbA1c) is essential for diabetes management. Immunoturbidimetry assays are widely used for HbA1c testing, offering a high-throughput, automated, and cost-effective solution.

The three most impactful pathogens were those responsible for tuberculosis (TB) at 65.1 million DALYs, malaria at 53.6 million, and HIV/AIDS at 52.1 million, highlighting their significant burden on global health. Notably, malaria parasites had the highest impact among children under five, contributing to 37.2 million DALYs, underscoring the urgent need for targeted interventions, improved access to treatment, and enhanced disease prevention strategies. The pandemic accelerated demand for immune response biomarkers such as ferritin, procalcitonin, D-dimer, and CRP, all of which can be analyzed using immunoturbidimetry reagents. Hospitals and diagnostic laboratories expanded their immunoturbidimetric testing capacities to monitor COVID-19-related complications, strengthening the market's growth trajectory. HIV/AIDS and hepatitis patients require frequent monitoring of immunoglobulins and inflammatory markers, both of which are efficiently measured using immunoturbidimetry-based assays. Tuberculosis remains a leading infectious disease, and the demand for serum protein analysis using immunoturbidimetry reagents has risen due to the need for accurate inflammation monitoring. Sepsis is a life-threatening condition requiring immediate detection of inflammatory biomarkers such as CRP, procalcitonin (PCT), and interleukin-6 (IL-6). Immunoturbidimetric tests provide fast and automated screening, enabling early intervention and reducing mortality rates.

Key Market Challenges

Low Adoption Rate of Automated Immunochemistry Products

The low adoption rate of automated immunochemistry products in developing economies presents a significant hindrance to the market's growth and advancement. While automated immunochemistry products offer numerous benefits, including enhanced efficiency, accuracy, and streamlined workflows, their uptake in these regions has been comparatively slow. One primary factor contributing to this challenge is the limited financial resources and budget constraints prevalent in many developing economies. The initial investment required for acquiring and implementing automated immunochemistry systems can be substantial, encompassing the cost of instrumentation, reagents, and the necessary infrastructure. In regions where healthcare budgets are constrained, prioritizing such investments can be a complex decision for healthcare facilities and institutions. Moreover, the maintenance and operational costs associated with automated immunochemistry systems may pose an ongoing financial burden for healthcare providers in these economies. This includes expenses related to instrument calibration, regular maintenance, and staff training. As a result, some healthcare facilities may be hesitant to make the transition from manual or semi-automated methods to fully automated immunochemistry platforms.

Key Market Trends

Rising Adoption of Automated and High-Throughput Diagnostic Systems

Automation is revolutionizing the clinical diagnostics industry, and immunoturbidimetry assays are increasingly being integrated into high-throughput laboratory analyzers. The demand for fast, accurate, and efficient testing solutions is leading to the widespread adoption of fully automated immunoassay platforms, which enhance diagnostic workflows and reduce human error.

Automated immunoturbidimetric systems can process a high volume of samples simultaneously, significantly reducing turnaround times and increasing laboratory productivity. Modern analyzers now incorporate artificial intelligence (AI) and machine learning (ML) algorithms to improve result accuracy, error detection, and predictive diagnostics. Automation ensures consistent and standardized immunoturbidimetric assay results, making it ideal for clinical laboratories, hospitals, and reference diagnostic centers. Hospitals and large diagnostic chains are investing in automated immunoturbidimetry analyzers to improve cost efficiency, reduce labor costs, and minimize reagent wastage. The integration of automated immunoturbidimetry systems with cloud-based data management and laboratory information systems (LIS) is expected to drive market growth by enabling seamless data sharing, remote monitoring, and enhanced laboratory efficiency.

Key Market Players

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

Report Scope:

In this report, the Global Immunoturbidimetry Reagents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoturbidimetry Reagents Market, By Type:

• Common Immune Turbidimetric Reagent
• Latex Enhanced Immune Turbidimetric Reagent

Immunoturbidimetry Reagents Market, By Application:

• Glycated hemoglobin
• Retinol Binding Protein
• C-Reactive Protein
• Anti-streptococcal hemolysin "O"
• Rheumatoid Factor
• Other

Immunoturbidimetry Reagents Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoturbidimetry Reagents Market.

Available Customizations:

Global Immunoturbidimetry Reagents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Immunoturbidimetry Reagents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Common Immune Turbidimetric Reagent, Latex Enhanced Immune Turbidimetric Reagent)
  • 5.2.2. By Application (Glycated hemoglobin, Retinol Binding Protein, C-Reactive Protein, Anti-streptococcal hemolysin "O", Rheumatoid Factor, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Immunoturbidimetry Reagents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoturbidimetry Reagents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Immunoturbidimetry Reagents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Immunoturbidimetry Reagents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Immunoturbidimetry Reagents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoturbidimetry Reagents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Immunoturbidimetry Reagents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Immunoturbidimetry Reagents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Immunoturbidimetry Reagents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Immunoturbidimetry Reagents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Immunoturbidimetry Reagents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Immunoturbidimetry Reagents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Immunoturbidimetry Reagents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Immunoturbidimetry Reagents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Immunoturbidimetry Reagents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Immunoturbidimetry Reagents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Immunoturbidimetry Reagents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Immunoturbidimetry Reagents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Immunoturbidimetry Reagents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Immunoturbidimetry Reagents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Immunoturbidimetry Reagents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Immunoturbidimetry Reagents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Immunoturbidimetry Reagents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Immunoturbidimetry Reagents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Immunoturbidimetry Reagents Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Danaher Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Siemens Healthineers AG
• 14.4. F. Hoffmann-La Roche AG
• 14.5. DIALAB GmbH
• 14.6. Shanghai Kehua Bio-Engineering Co Ltd
• 14.7. Randox Laboratories Ltd
• 14.8. Beijing Leadman Biochemistry Co Ltd
• 14.9. Fujifilm Corp
• 14.10.Mindray Medical International Ltd

15. Strategic Recommendations

16. About Us & Disclaimer